Provides guidance for the quarter ending June 30, 2025 of $60 – $63 million in net product revenue and cash operating expenses of $45 – $50 million.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Wins Court Ruling for LUMRYZ Expansion
- Avadel Pharmaceuticals announces favorable ruling in appeal of injunction
- Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
- Is AVDL a Buy, Before Earnings?
- Avadel, nference announce publication of data on sodium oxybate